Fact checked byRichard Smith

Read more

October 02, 2024
2 min read
Save

Hypothyroidism does not worsen rate of cognitive decline for perimenopausal women

Fact checked byRichard Smith
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Key takeaways:

  • Hypothyroidism did not have a significant effect on a decline in processing speed over time in SWAN.
  • Working memory and episodic memory did not significantly change during follow-up.

Women with hypothyroidism receiving levothyroxine treatment experienced similar cognitive decline during menopause as those without thyroid disease, according to data published in Thyroid.

In the Study of Women’s Health Across the Nation (SWAN), women aged 42 to 52 years at baseline completed cognitive function tests assessing processing speed, working memory and episodic memory during a mean follow-up of 13 years. During follow-up, researchers found declines in processing speed were not significantly greater for women with hypothyroidism, and no decreases in working memory or episodic memory were observed for the full study group.

Matthew Ettleson, MD

“Some cognitive decline during menopause and in the years after is expected, and hypothyroidism, if properly treated, would not be expected to make this worse,” Matthew Ettleson, MD, clinical fellow at the University of Chicago, told Healio. “Therefore, if there is a decline in cognitive function beyond what is expected, a thorough investigation is warranted, including thyroid function testing. However, for most women, if thyroid function testing is normal (whether they have hypothyroidism or not), I would consider alternative explanations for the decline in cognitive function.”

Researchers obtained cognitive function data from 2,033 SWAN participants, of whom 227 had levothyroxine-treated hypothyroidism (mean age, 49.8 years; 59.9% white) and 1,806 had no thyroid disease (mean age, 50 years; 45.1% white). Cognitive function testing was conducted between 2000 and 2017. Processing speed was measured through the Symbol Digit Modalities Test. Working memory was evaluated using a digit span backward evaluation. The East Boston Memory Test was used to assess episodic memory.

In the initial cognitive function test, women with hypothyroidism had a higher processing speed score (mean score, 56.5 vs. 54.4; P = .006) and working memory score (mean score, 6.8 vs. 6.4; P = .018) than women without thyroid disease. No difference in episodic memory score was observed between the two groups at baseline.

During follow-up, participants had a significant annual decline in processing speed (beta = –0.013; P < .001). Hypothyroidism did not have a significant effect on cognitive function decline. There was no significant decline in working memory or episodic memory decline during the study, and hypothyroidism did not have a significant effect on the change in either assessment score.

“In designing this study, my concern was that we would find a difference [between groups], and it is reassuring that we did not,” Ettleson said. “However, the literature remains very mixed on this topic, so we shouldn’t be surprised by the findings. We only had data available on a select number of cognitive tests. Therefore, it’s possible that other domains of cognitive function that were not tested were indeed worse in those with hypothyroidism.”

Ettleson also noted there was a limited amount of thyroid function data available in SWAN, making it difficult for researchers to control for thyroid hormone levels in the study.

“We still need to learn more about those patients that have persistent symptoms on levothyroxine,” Ettleson said. “Are there some unique characteristics that could help clinicians better identify and treat these individuals?”

For more information:

Matthew Ettleson, MD, can be reached at matthew.ettleson@uchospitals.edu.